- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04176120
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)
A Multicenter Phase 3 Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)
Study Overview
Status
Intervention / Treatment
Detailed Description
This trial is designed as a confirmatory study of the benefits and risks of TTAX01 when used in the treatment of Wagner Grades 3 and 4 DFU. Experience with the use of a cryopreserved umbilical cord (UC) product in treating such wounds, both prior to this Investigational New Drug application (IND) and under this IND, has indicated that a frequency of application of no shorter than every 4 weeks is associated with better than expected outcomes. Although treatment cannot be blinded, a "standard care only" arm is included to control for the benefits of aggressive baseline debridement combined with aggressive (6 weeks systemic) antibiotics. Current treatment guidelines indicate that aggressive debridement plus 1-2 weeks of antibiotics, or, minor debridement plus 6 weeks of antibiotics, would produce equivalent outcomes, although the evidence is not strong. By utilizing both maximum debridement and maximum antimicrobial therapy, the standard care described in this protocol may result in healing rates somewhat superior to current standard practice.
The design of this confirmatory study is matched to the design of the Phase 2 efficacy study TTCRNE-1501, with the exception of extending the primary endpoint from 16 to 26 weeks, and utilizing a proportional risk analysis rather than a landmark analysis. This design consideration is based on analysis of previous studies, and a desire to fold data from every visit into the primary analysis, rather than generating an excessive number of secondary endpoints.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Kathleen Ripp
- Phone Number: 786-753-2037
- Email: kripp@biotissue.com
Study Contact Backup
- Name: Stanley Harris
- Phone Number: 678-722-9923
- Email: sharris@biotissue.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94117
- BayArea Foot Care
-
Sylmar, California, United States, 91342
- UCLA Olive View
-
-
Florida
-
Miami, Florida, United States, 33125
- University of Miami
-
West Palm Beach, Florida, United States, 33407
- Paley Orthopedic & Spine Institute
-
-
Illinois
-
North Chicago, Illinois, United States, 60064
- Rosalind Franklin University
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Medical Center
-
-
New York
-
New York, New York, United States, 10019
- Mount Sinai West
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
-
Ohio
-
Richmond Heights, Ohio, United States, 44143
- University Hospitals Richmond Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Vanderbilt University Medical Center
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- JPS
-
McAllen, Texas, United States, 78501
- Futuro Clinical Trials, LLC
-
San Antonio, Texas, United States, 78224
- Bio-X-Cell Research
-
-
Utah
-
Saint George, Utah, United States, 84470
- Foot & Ankle Institute
-
-
Virginia
-
Roanoke, Virginia, United States, 24013
- Carilion Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The subject has signed the informed consent form
- The subject is male or female, at least 18 years of age inclusive at the date of Screening
- The subject has confirmed diagnosis of Type I or Type II diabetes
- The subject's index ulcer is located on the plantar surface, inter digital, heel, lateral or medial surface of the foot
- The subject has an index ulcer with visible margins having an area ≤ 12.0 cm2 when measured by the electronic measuring device at Screening
- The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule
- The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (X-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis
- The subject has an ABI ≥ 0.7 to ≤ 1.3 or TcPO2 ≥ 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure ≥ 50 mmHg
- The subject is under the care of a physician for the management of Diabetes Mellitus
- The subject is willing to return for all mandatory visits as defined in the protocol
- The subject is willing to follow the instructions of the trial Investigator
Exclusion Criteria:
- The subject's index ulcer is primarily located on the dorsal surface of the foot
- The subject's index ulcer can be addressed by primary closure through the completion of the initial or staged surgical procedure
- The subject has a contralateral major amputation of the lower extremity
- The subject has a glycated hemoglobin A1c (HbA1c) level of > 12%
- The subject has been on oral steroid use of > 7.5 mg daily for greater than seven (7) consecutive days in 30 days before Screening
- The subject has been on parenteral corticosteroids, or any cytotoxic agents for seven consecutive days in the period of 30 days before Screening
- The subject is currently taking the type 2 diabetes medicine canagliflozin (Invokana™, Invokamet™, Invokamet XR™)
- The subject has malignancy or a history of cancer, other than non-melanoma skin cancer, in five years before Screening
- The subject is pregnant
- The subject is a nursing mother
- The subject is a woman of child-bearing potential who is unwilling to avoid pregnancy or use an appropriate form of birth control (adequate birth control methods are defined as: topical, oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner).
- The subject is unable to sustain off-loading as defined by the protocol
- The subject has an allergy to primary or secondary dressing materials used in this trial
- The subject has an allergy to glycerol
- The subject's index ulcer is over an acute Charcot deformity
- The subject has had previous use of NEOX®, CLARIX®, or TTAX01 applied to the index ulcer
- Per Investigator's discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments listed in the protocol or the subject currently has sepsis, i.e., life-threatening organ dysfunction caused by a dysregulated host response to infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TTAX01
TTAX01 plus standard care
|
TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.
TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue.
TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP).
TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
Standard care is defined in this protocol to consist of the following:
|
Other: Control
Standard Care alone
|
Standard care is defined in this protocol to consist of the following:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete wound healing
Time Frame: over 26 weeks
|
Time from baseline to initial observation of healing, where healing has been confirmed at two consecutive visits each two weeks apart.
|
over 26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete wound healing
Time Frame: by Week 50
|
Proportion of wound healed
|
by Week 50
|
Wound durability
Time Frame: by Week 50
|
Proportion of wounds that re-ulcerate
|
by Week 50
|
Limb preservation
Time Frame: by Week 50
|
proportion of minor and major amputations following the initial procedure
|
by Week 50
|
Patient-reported mobility
Time Frame: Baseline to End of Study (approximately 50 weeks)
|
compare total score on PROMIS Health Organization Neuro-QoL 'lower extremity function'; scale from 1-5; higher scores indicate better self-reported health
|
Baseline to End of Study (approximately 50 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Herbert Slade, MD, Chief Medical Officer
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TTAX01-CR003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Infection
-
MicuRxRecruitingDiabetic Foot InfectionSpain, China, United States, Estonia, Latvia, Portugal, Bulgaria, Greece, Italy, Lithuania, Puerto Rico
-
Microbion CorporationCUBRC, MTEC, and US NavyActive, not recruitingDiabetic Foot | Diabetic Foot InfectionUnited States
-
Centre Hospitalier Universitaire de NīmesRecruitingDiabetic Foot InfectionFrance
-
Hospices Civils de LyonCompletedDiabetic Foot InfectionFrance
-
Prisma Health-UpstateTerminated
-
TaiGen Biotechnology Co., Ltd.CompletedDiabetic Foot InfectionsTaiwan, United States, South Africa, Thailand
-
Merck Sharp & Dohme LLCCompletedFoot Infections in Diabetic Patients
-
Balgrist University HospitalRecruitingSurgical Wound | Infection | Antibiotic Side Effect | Diabetic Foot InfectionSwitzerland
-
BioMed Valley Discoveries, IncTerminatedDiabetic Foot InfectionUnited States
-
Methodist Health SystemRecruitingDiabetic Foot InfectionUnited States
Clinical Trials on TTAX01
-
Tissue Tech Inc.CompletedDiabetic Foot Infection | Non-healing Wound | Non-healing Diabetic Foot UlcerUnited States
-
Tissue Tech Inc.RecruitingDiabetic Foot Infection | Non-healing Wound | Non-healing Diabetic Foot UlcerUnited States
-
Tissue Tech Inc.CompletedVenous Leg UlcerUnited States